CURE® Breast Cancer 2022 Special Issue

Enhertu's FDA approval marked a major milestone in the breast cancer space, as it was the first drug to be approved for patients with HER2-low disease.

It is essential that patients with breast cancer speak up to their health care providers, be it advocating for genetic testing or discussing symptoms.

Chest numbness following a mastectomy can be truly daunting, but patients with breast cancer don’t have to suffer in silence — and it may not be something they have to live with.

An FDA approval put Ki-67 scoring — which may predict tumor growth — in the spotlight, but what that means long term to patients depends on who you ask.

There are ways to manage the fear of cancer recurrence, so it doesn’t become overwhelming or debilitating. Physicians like me and a network of resources are here to help.

The designation of HER2-low status is rapidly reshaping how researchers and care providers not only think about, but also treat, breast cancer.